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G protein-coupled receptors (GPCRs) modulate most physiological functions but are also
critically involved in numerous pathological states. Approximately a third of marketed drugs
target GPCRs, which places this family of receptors in the main arena of pharmacological
pre-clinical and clinical research.The complexity of GPCR function demands comprehensive
appraisal in native environment to collect in-depth knowledge of receptor physiopathologi-
cal roles and assess the potential of therapeutic molecules. Identifying neurons expressing
endogenous GPCRs is therefore essential to locate themwithin functional circuits whereas
GPCR visualizationwith subcellular resolution is required to get insight into agonist-induced
trafﬁcking. Both remain frequently poorly investigated because direct visualization of
endogenous receptors is often hampered by the lack of appropriate tools. Also, monitoring
intracellular trafﬁcking requires real-time visualization to gather in-depth knowledge. In this
context, knock-in mice expressing a ﬂuorescent protein or a ﬂuorescent version of a GPCR
under the control of the endogenous promoter not only help to decipher neuroanatomical
circuits but also enable real-time monitoring with subcellular resolution thus providing
invaluable information on their trafﬁcking in response to a physiological or a pharmacological
challenge.This review will present the animal models and discuss their contribution to the
understanding of the physiopathological role of GPCRs.Wewill also address the drawbacks
associated with this methodological approach and browse future directions.
Keywords: G protein-coupled receptors, fluorescent protein, knock-in, mouse model, drug design, biased agonism,
receptor trafficking
INTRODUCTION
G protein-coupled-receptors (GPCRs) are proteins composed
of seven transmembrane alpha helices with an extracellular
N-terminus and an intracellular C-terminus (Rosenbaum et al.,
2009). They represent one of the largest gene families in mam-
mals and humans (Lagerström and Schiöth, 2008, and references
therein). GPCRs can respond to various stimuli such as pho-
tons, ions, lipids, peptides, odorants, nucleotides, hormones, or
neurotransmitters (Congreve et al., 2014). There are ﬁve human
GPCR families: Rhodopsin, Secretin, Adhesion, Glutamate, and
Frizzled/Taste2 with the rhodopsin receptor family being the
largest. More than half of the 800 human GPCRs are classiﬁed
as chemosensory taste or olfactory receptors (Lagerström and
Schiöth, 2008; Heng et al., 2013). The remaining human GPCRs
-roughly 370- may be involved in pathophysiological processes
and are therefore potentially drugable targets. Indeed, metabolic,
inﬂammatory, infectious or neurodegenerative diseases as well as
cancer all involve a plethora of GPCRs (Heng et al., 2013). As
many GPCRs belong to neuromodulatory systems (van den Pol,
2012), a large number of them are targeted by drugs in the context
of nervous system disorders such as pain, drug addiction, anxi-
ety, depression, sleep disorders, and neuroendocrine deregulation
(Heng et al., 2013). Altogether, GPCRs represent the targets of
about one third of marketed drugs (Overington et al., 2006).
Understanding the roles of GPCRs requires both in depth
small scale investigation and overview. Indeed, GPCR expression,
function, modulation, and trafﬁcking properties remain difﬁcult
to fathom and reﬂect the complex, highly regulated pathways in
which they are involved. The study of GPCRs in physiology and
disease therefore requires integrative and functional systems. This
is especially true when considering the central nervous system
(CNS) where neuronal networks are complex and intermingled.
It is therefore of utmost importance to identify and delineate cells
that express the GPCR of interest. In the majority of studies, map-
ping GPCR expression was overcast by poor antibody speciﬁcity.
The measure of this limitation was only fully appreciated when
genetically modiﬁed mice which were deﬁcient for the GPCR of
interest became available, emphasizing the insufﬁcient speciﬁcity
of the commonly used antibodies, thereby prompting the search
for new technologies to monitor receptor trafﬁcking, decipher
activated intracellular signaling cascades or investigate functional
outcomes of GPCR activation in integrated systems, and particu-
larly in neuronal networks (Marder, 2012). Among the options
which were being explored, ﬂuorescent proteins (FPs) isolated
from natural organisms attracted special interest as they appeared
to be very promising tools to achieve these goals. There are many
advantages to using ﬂuorescent molecular tags; the inherent ﬂuo-
rescence is directly visible, chemically resistant to ﬁxation and can
be used in time-course studies in living cells for tracking receptor
trafﬁcking events (Kallal and Benovic, 2000).
The Green FP (GFP) was the ﬁrst FP used in biology. This pro-
tein is composed of 238 amino acids (roughly 27 kDa) and was
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isolated from the jellyﬁsh Aequorea victoria (Shimomura et al.,
1962, for review see Tsien, 1998). A mutant form of GFP called
enhanced GFP (eGFP) was later generated, with improved quan-
tum yield efﬁciency and higher solubility, making eGFP a popular
reporter molecule (Cormack et al., 1997). The additional mutants
that were created offer a large palette of ﬂuorescence, ranging
from violet to far red, thus opening new perspectives, includ-
ing the possibility of co-expressing two or more FP in the same
cell, whereby protein interactions could be investigated (Heim
and Tsien, 1996). Likewise, this can be achieved by simultane-
ously expressing eGFP and mcherry, a stable monomeric mutant
derived from the red ﬂuorescent protein (RFP) DsRed, the latter
was isolated from the coral Discosoma sp. (Campbell et al., 2002;
Shaner et al., 2004). Additional variants derived from the GFP or
DsRed were also generated and possess fast maturation, improved
pH stability and photostability (reviewed in Shaner et al., 2007;
Subach et al., 2009). The development of these FPs has been par-
alleled by technological advances in the ﬁeld of live cell imaging
that have brought high quality approaches for analysis of biolog-
ical processes in a time- and space-dependent manner (Nienhaus
and Nienhaus, 2014).
Validation of drug targets and pharmacological mechanisms
cannot be achieved without in vivo preclinical studies for which
mouse models provide a mammalian background and genetic
tools of great value (Doyle et al., 2012; Bradley et al., 2014). In
order to address GPCR function in vivo, tracking endogenous
receptors with FPs therefore represents indisputable added value.
In the following sections, we will review and comment on the use
of FPs that has helped to shed light on endogenous GPCR function
in vivo.
IN VIVO EXPRESSION OF FP UNDER GPCR PROMOTER
FROM TRANSGENIC TO KNOCK-IN MOUSE LINES
Transgenic mouse lines expressing FPs under the control of pro-
moters for a GPCR or an endogenous peptide were created. A
number of reporter mice generated using bacterial artiﬁcial chro-
mosomes (BACs) were part of a project called gene expression ner-
vous system atlas (GENSAT) http://www.gensat.org/index.html
(Gong et al., 2003) that produced an important set of data relative
to gene expression which could be used for deciphering the devel-
opmental implications and network dynamics of selected genes
of interest. On the account that speciﬁc CNS genes are most
often expressed in a particular cell population or anatomically
deﬁned structure, tandem dimer Tomato (td-Tomato), a RFP, or
eGFP-labeling of these cells renders analysis of the anatomical,
physiological and biomolecular properties of a chosen subtype
of neurons accessible. Overall, transgenic reporter mouse lines
have proven to be extremely useful for the precise mapping of
GPCR and endogenous ligands expression in the nervous sys-
tem, and are suitable for analysis of cell populations (Heintz,
2001).
The shortcomings of the transgenic mouse models are, how-
ever, manifold (Haruyama et al., 2009). (1) Transgenic expression
results in overexpression compared to wild type animals. (2)
Low efﬁciency of transmission to offspring may be caused by
mosaic expression of the transgene in founder animals. Indeed,
high copy number insertion of transgenes is more vulnerable
to epigenetic silencing, which reduces the transgene expression
level in successive generations. (3) Expression in unexpected
tissues or timeframes may result from transgene insertion in
genomic regions containing an endogenous promoter or enhancer.
(4) Silencing or ectopic expression can be caused by positional
effects. Transgene insertion can take place into transcriptionally
inactive regions of the genome, or can be affected by neigh-
boring repressor sites. Transgene insertion being, in essence,
random, the possibility of disrupting the normal genome is
very high. As a consequence, the erratic nature of the trans-
gene insertion may result in unpredicted and/or detrimental
phenotypes and off-target effects. As an example, many groups
used BAC transgenic mice expressing eGFP driven by the pro-
moter for either D1 or D2 receptors, the dopamine receptor
1 or 2, respectively (Lee et al., 2006; Bertran-Gonzalez et al.,
2008; Valjent et al., 2009; Tian et al., 2010; Kramer et al., 2011;
Chan et al., 2012). Mainly, work published using these two
BAC transgenic mice successfully identiﬁed neurons expressing
dopamine receptors and delineated dopaminergic connectivity
in the CNS. However, Kramer et al. (2011) brought evidence of
molecular and behavioral alterations in Drd2-eGFP BAC trans-
genic mice comprising novel environment hyperactivity, reduced
locomotor response to cocaine, and D2 receptor agonist hyper-
sensitivity. These effects were presumably due to unfortunate
insertion of the BAC, which caused receptor overexpression
(Kramer et al., 2011).
KNOCK-IN MICE: TOWARD MORE SPECIFIC MODELS
To overcome the limitations associated with the use of trans-
genic mice, efforts were made to generate knock-in animals in
which a FP is introduced at the locus of interest by homologous
FIGURE 1 | Schematic diagram of genetic constructions of knock-in
mice expressing a fluorescent protein (FP) under the control of an
endogenous GPCR promoter. (A) Endogenous GPCR gene layout.
(B) Knock-in FP expressed under the control of the endogenous GPCR
promoter: the endogenous GPCR gene is replaced by the FP coding
sequence. (C)The FP coding sequence is knocked into the truncated gene
coding for the native GPCR, resulting in genetic invalidation of the receptor.
(D) Insertion of an internal ribosomal entry site (IRES) downstream of the
endogenous GPCR gene, ahead of the FP coding sequence. Native GPCR
expression is maintained, and the FP is also expressed under the control of
the endogenous GPCR promoter. (E)The FP sequence is inserted in frame
in place of the stop codon in the endogenous GPCR gene giving rise to a
ﬂuorescent fusion protein in which the FP is fused to the C -terminus of the
functional GPCR in conditions of native expression.
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recombination. Several strategies are used (see Figure 1). Mod-
els in which an FP is expressed either under the control of an
endogenous GPCR promoter are valuable and reliable tools for
localization and characterization of cell population which express
the GPCR of interest. However, such strategies present a signiﬁ-
cant drawback since the GPCR is non-functional following partial
or total replacement of its coding sequence by the FP coding
one. The FP is thus expressed in appropriate cells, but the pre-
cise subcellular localization and function of the receptor cannot
be examined and the ﬁnal outcome, in the case of homozygous
animals, is the absence of the functional GPCR, equivalent to a
knock-out phenotype. This limitation can be circumvented by the
introduction of an internal ribosomal entry site (IRES) sequence,
whereby expression of the endogenous GPCR is maintained and
the chosen FP is expressed under control of the endogenous
promoter.
Chemokine receptors
Jung et al. (2000) published the ﬁrst knock-in mouse in which
an FP was expressed under a GPCR promoter. The aim was to
track cells which expressed the Fractalkin (CX3C) chemokine
receptor CX3CR1, using a GFP knock-in strategy by replac-
ing the ﬁrst 390 bp of exon 2 of the CX3CR1 gene that
encodes the receptor N-terminus by a eGFP-coding sequence,
enabling direct identiﬁcation of peripheral blood cells and brain
microglia expressing CX3CR1 (see Table 1). In heterozygous
animals, CX3CR1 expression remained detectable because these
CX3CR1+/GFP heterozygous animals possess one allele for ﬂu-
orescence visualization of cells expressing the GPCR of interest
and one allele for expression of the functional receptor. Since
CX3CR1 and its ligand Fractalkin play a role in immunological
and inﬂammatory processes, this model was used to investi-
gate microglia proliferation during early embryonic spinal cord
invasion (Rigato et al., 2012) neuron-glia interactions in the con-
text of nerve injury or neuroinﬂammation (Garcia et al., 2013)
and in neurodegenerative diseases such as Alzheimer’s disease
(Fuhrmann et al., 2010), or Parkinson’s disease (Virgone-Carlotta
et al., 2013).
A follow-up to this knock-in mouse was published in 2010.
In their paper, Saederup et al. (2010) designed a mouse with
another single FP, RFP (a DsRed variant) replacing the ﬁrst
279 base pairs of the open reading frame coding for the
chemokine receptor type 2 (CCR2), and crossed the heterozy-
gous CCR2+/RFP and homozygous CCR2RFP/RFP knock-in ani-
mals with the previously published CX3CR1GFP/GFP homozygous
animals, in order to obtain heterozygous double knock-in ani-
mals CX3CR1+/GFPCCR2+/RFP. The two chemokine receptors
are expressed by distinct monocyte populations, therefore the
red and green FPs constitute an elegant “two-colored” mouse
model which was ideally suited for immunological studies (see
Table 1). Indeed, because the immune system is constituted
of cells that circulate in blood and lymph vessels, mature cells
do not constitute a solid organ and are not restricted by con-
nective tissue, therefore immune cell tracking is essential. Both
the double heterozygous knock-in animals and the ﬁrst mouse
line (CX3CR1+/GFP knock-in), were used to study and ade-
quately quantify macrophage and monocyte population dynamics
in a model of autoimmune tissue inﬂammation (experimental
autoimmune encephalomyelitis), which recapitulates an animal
model of multiple sclerosis (MS). In a subsequent study, the
same group unveiled myeloid lineage and microglial chemokine
receptor changes at embryonic stages 8.5–13.5, monitored CNS
colonization by cells of interest, during development and in an
MS model using adult mice (Mizutani et al., 2012). The knock-in
models thus yielded exciting and fundamental results relative to
the identiﬁcation of cells expressing the designated GPCRs, and a
ﬁne description of cellular population changes in various disease
paradigms.
Oxytocin receptors
Yoshida et al. (2009) engineered a mouse line in which a 5′
fragment of exon 3 of the oxytocin receptor (OTR) gene was
replaced by a sequence coding for Venus FP, a yellow FP vari-
ant (Nagai et al., 2002). The recombined allele did not encode
functional OTR but heterozygous animals retained radiolabelled
oxytocin binding patterns through the intact allele, while enabling
direct visualization of Venus in oxytocin expressing cells (Yoshida
et al., 2009). Immunohistochemical analysis of brain sections
from these animals revealed that there was a high expression
of Venus (hence OTR) in monoaminergic areas of the brain
in agreement with in situ hybridization (ISH) studies (Vaccari
et al., 1998). However, the approach provided more sensitive
detection of OTR expression by identifying additional areas and
cells expressing Venus ﬂuorescence among which serotoninergic
ones. This study was the ﬁrst to show evidence for interac-
tion between oxytonergic and serotonergic systems in a pathway,
which modulates anxiety. In a following study, these knock-
in mice were used to map OTR expression in the spinal cord;
shedding light on the modulatory role of oxytocinergic networks
involved in spinal cord functions, such as nociception (Wrobel
et al., 2011).
Taste receptors
Sensing of the chemical categories which are responsible for sweet,
sour or umami taste is speciﬁcally encoded by GPCRs expressed
on primary taste neurons (Liman et al., 2014). The taste recep-
tor family 1 (Tas1r) belongs to class C GPCRs and function as
obligatory heteromers, meaning that two GPCRs of different sub-
types are associated and interact to form a functional entity. The
taste receptor family 2 (Tas2r), on the other hand, are currently
classiﬁed among class A GPCRs (Alexander, 2013).
In order to study the distribution of taste receptors in the
mouse gustatory tissue, Voigt and collaborators engineered two
knock-in mouse lines which they subsequently crossed in order to
obtain double knock-in animals in which the open reading frame
encoding the receptor was replaced by the sequence coding for
the mcherry or humanized Renilla (hr)GFP under the control of
Tas1r1 (umami taste receptor) or Tas2r131 (bitter taste receptor)
promoters, respectively (Voigt et al., 2012). This approach permit-
ted identiﬁcation of cells expressing mcherry under the control
of the Tas1r1 promoter in the lingual papillae, soft palate, fungi-
form and foliate papillae, conﬁrming previous ﬁndings (Hoon
et al., 1999; Stone et al., 2007) but also in extra-gustatory tissues
(lung epithelium, testis, thymus) which had not been investigated
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Table 1 | Knock-in mice expressing fluorescent proteins under the control of G protein-coupled receptor (GPCR) endogenous promoters.
Targeted GPCR Fluorescent
protein
Identified
cell type
Model Therapeutic potential Reference
Insertion of FP sequence at the GPCR gene locus
Chemokine CX3CR1 eGFP Immune cells Peritonitis
Nerve injury
Neuroinﬂammation
Neurodegenerative
diseases
Jung et al. (2000)
Microglia Population dynamics in
embryonic development
Rigato et al. (2012)
Microglia Neurodegeneration Alzheimer Fuhrmann et al. (2010)
Microglia Neuroinﬂammation Parkinson Virgone-Carlotta et al. (2013)
Chemokine CCR2 RFP Immune cells Experimental autoimmune
encephalomyelitis
Neuroinﬂammation
Neurodegenerative
diseases
Saederup et al. (2010)
Chemokine CX3CR1
x
Chemokine CCR2
eGFP
RFP
Immune cells Experimental autoimmune
encephalomyelitis
Neuroinﬂammation
Neurodegenerative
diseases
Saederup et al. (2010)
Myeloid cells
Microglia
Experimental autoimmune
encephalomyelitis
Population dynamics in
embryonic development
Mizutani et al. (2012)
Oxytocin Venus Brain distribution Anxiety related Psychiatric disorders Yoshimura et al. (2001)
Spinal cord distribution Nociception/pain Wrobel et al. (2011)
Mrgprd eGFPf Sensory projections to
epidermis
Nociception/pain Zylka et al. (2005)
Sensory projections to tooth
pulp
Nociception/dental pain Chung et al. (2012)
Taste TasR1 mcherry Taste cells in taste buds and
peripheral tissue
– Voigt et al. (2012)
Taste Tas2R131 hrGFP Taste cells in taste buds and
peripheral tissue
– Voigt et al. (2012)
Taste TasR1
x
Taste Tas2R131
mcherry
hrGFP
Taste cells in taste buds and
peripheral tissue
– Voigt et al. (2012)
GPCR-IRES-FP expression
Mas-related Mrgprd eGFPf Sensory projections to
epidermis
Nociception/pain Zylka et al. (2005)
Cannabinoid CB1 Td-Tomato Neurons Chronic cocaine injection Drug addiction Winters et al. (2012)
before (Voigt et al., 2012). Expression of hrGFP under the control
of Tas2r131 promoter was in accordance with previously ﬁnd-
ings describing taste receptor distributions (Behrens et al., 2007),
showing abundant hrGFP expression in taste buds of the pos-
terior tongue, vallate palate and foliate palate. In addition, it
uncovered, for the ﬁrst time, expression restricted to only half
of the bitter sensor cells (Voigt et al., 2012). Double knock-in ani-
mals lacked both taste receptors, but expressed FPs in the targeted
cells [veriﬁed by reverse transcription polymerase chain reaction
(RT-PCR), ISH and immunohistochemistry]. This genetic label-
ing technique served for population distribution studies, which
was until then unachievable, given the fact that Tasr expres-
sion is sparse in cells, and that the available antibodies lack
speciﬁcity. The double knock-in animals yielded a valuable and
detailed cartography of taste receptors in the mouse, and revealed
that distinct chemosensory cell populations mediate speciﬁc and
non-overlapping taste qualities.
Mas-related-G-protein coupled receptors
Mas-related-G-protein coupled receptor member D (Mrgprd)
belongs to a GPCR family of approximately 50 members, related
to Mas1 (oncogene-like MAS), called Mrgs. Mrgs are suspected to
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be involved in development, regulation and function of nocicep-
tive neurons or nociceptors (Dong et al., 2001) and are expressed
in a subset of nociceptors, which are small diameter primary sen-
sory neurons in dorsal root ganglia (DRG) directly involved in
processing nociceptive stimuli, especially itch (Liu et al., 2012).
Zylka et al. (2005) observed similar expression patterns of the
eGFPf (a farnesylated form that anchors the FP to the cytoplas-
mic leaﬂet of the lipid bilayer) in nociceptors, and projections
of the sensory neurons to the epidermis using knock-in mice in
which the open reading frame coding forMrgprd is replaced by the
sequence encoding the eGFPf or knock-in animals in which the
eGFPf sequence is inserted behind an IRES element downstream
of the mouse Mrgprd gene (Zylka et al., 2005). This demonstrates
that both strategies can be equally used for cellular mapping. In
addition, similar projection proﬁles in the epidermis validated
the eGFPf knock-in mouse for axonal tracing by comparison
with the widely used human placental alkaline phosphatase teth-
ered to the extracellular surface of the plasma membrane by a
glycophosphatidylinositol linkage.
In a later study, the knock-in mouse model expressing eGFPf
at the Mrgprd locus was used to identify non-peptidic nociceptive
neuronsof trigeminal ganglia innervating toothpulp (Chung et al.,
2012). This opens future application of thismodel to study the role
and function of the targeted GPCR in dental pain.
Cannabinoid receptors
The endocannabinoid system plays roles in memory, appetite,
stress and immune processes, as well as motivation and emo-
tional responses and modulates the effects of some drugs of
abuse (Pertwee, 2006; Tan et al., 2014). In the nucleus accum-
bens (NAc), a brain structure which has a crucial role in reward
processing and a decisive inﬂuence on emotional andmotivational
responses, cannabinoid receptor 1 (CB1) expression is limited but
nevertheless essential for cocaine-induced reward in mice (Mar-
sicano and Lutz, 1999). In order to further identify and delineate
the cellular and electrophysiological properties of CB1 recep-
tor expressing cells in the NAc, Winters et al. (2012) designed a
knock-in mouse line in which an IRES element ensures expres-
sion of both CB1 receptors and td-Tomato under the control of
the CB1 promoter. Importantly, this mouse line still expressed
functional CB1 receptors. Neurons expressing CB1 receptors were
readily visualized in the NAc and their distribution was in accor-
dance with previous data on CB1 receptor localization using ISH
or immunohistochemistry (Mailleux and Vanderhaeghen, 1992;
Tsou et al., 1997). This mouse line enabled to identify of cells and
to explicitly demonstrate biochemical and signaling properties of
a particular neuronal population of fast-spiking interneurons in
the NAc which impacts on the NAc projections and connectiv-
ity. Results also revealed functional impact of cocaine on these
neurons (Winters et al., 2012).
GPCR-FP FUSION FOR IN VIVO FUNCTIONAL AND MAPPING
STUDIES
INITIAL VALIDATION OF GPCR-FP FUSIONS IN HETEROLOGOUS
SYSTEMS
Fusions between a GPCR and an FP as tools to monitor the
GPCR subcellular localization and trafﬁcking were ﬁrst studied
in heterologous systems. Two fusion options were considered:
either the FP at the N-terminus or at the C-terminus. A vast
majority of GPCRs do not have cleavable N-terminus signal
sequences that target them to the plasma membrane. Intro-
duction of a foreign sequence ahead of their N-terminus has
been shown to disrupt surface addressing, and correct mem-
brane targeting and insertion therefore requires introduction
of an additional foreign signal sequence in front of the fusion
construct (McDonald et al., 2007). If proper cell surface expres-
sion is indeed restored, introduction of such a signal sequence
nonetheless strongly impacts on the relative ratio between surface
expression and intracellular distribution by substantially increas-
ing the amount of protein at the cell surface (Dunham and
Hall, 2009, and references therein). Hence, such fusion pro-
teins are not well suited to mimic the responses of endogenous
GPCRs to agonist stimulation and were not used for in vivo
studies.
Concerns have also been raised regarding in frame insertion of
the FP at the C-terminus of the GPCR by substitution of the stop
codon. The presence of a 27 kDa beta barrel at the intracellular
extremity of the GPCR could indeed interfere with intracellular
scaffold partners and modify signaling or internalization pro-
cesses thus defeating the object when studying GPCR signaling
properties. However, many studies performed in mammalian cells
on a large number of GPCRs strongly suggest that addition of
GFP at the C-terminus does not signiﬁcantly affect subcellu-
lar distribution in the basal/unstimulated state, ligand binding
or agonist-induced receptor phosphorylation and internalization,
(for reviewKallal andBenovic, 2000). McLean andMilligan (2000)
expressed β1- and β2-adrenergic receptors fused to a C-terminal
eGFP mutant in human embryonic kidney (HEK 293) cells. These
authors concluded that the presence of the eGFP did not inﬂuence
ligand binding but decreased the agonist-induced internalization
kinetics without affecting the intracellular fate of the receptor.
Trafﬁcking of the fusion protein was qualitatively maintained,
but was quantitatively slightly modiﬁed compared to native pro-
teins. This study therefore supports the use of such fusions to
monitor endogenous receptor subcellular localization. Similarly,
the genetic construction encoding the delta opioid (DOP) recep-
tor fused with eGFP protein at the C-terminus was expressed in
transfected HEK 293 cells, and the fusion did not alter opioid
ligand binding afﬁnity or signaling (Scherrer et al., 2006). This
construct was later successfully used to express a functional DOP-
eGFP fusion in mice by knocking the modiﬁed sequence into
the endogenous DOP receptor locus (Scherrer et al., 2006, see
below).
In some cases, however, FP fusion at the GPCR C-terminus
had deleterious effects. Defective targeting to the cell surface was
reported for the melanocortin 2 receptor fused to the GFP in HEK
293 cells (Roy et al., 2007) and no recycling was observed for the
muscarinic M4 receptor fused to a C-terminal red variant of GFP
in neuroblastoma/glioma hybrid cells (NG108-15 cells; Madziva
and Edwardson, 2001). In both cases, impairment was more likely
to be due to gross overexpression rather than fusion of the FP to
the C-terminus. High levels of expression of a GPCR in a non-
native environment can indeed artiﬁcially elicit properties and
interactions that would not occur in vivo. Moreover, cell lines
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used for heterologous expression may provide different intracel-
lular machinery for complex protein folding or post-translational
modiﬁcations compared to naturally producing cells. This repre-
sents an additional limitation to the study of GPCR functions and
prompted to develop in vivo approaches.
FROM TRANSGENIC TO KNOCK-IN MOUSE LINES
Papay et al. (2004) reported a transgenic mouse model of a ﬂuo-
rescent tagged GPCR. The construct they described was composed
of a 3.4 kb fragment of the mouse endogenous α1B adrenocep-
tor promoter, the human α1B adrenoceptor coding sequence with
C-terminal fusion eGFP sequence. The resulting founder lines
were characterized, and high expression levels were observed in
all tissues that naturally express α1B adrenoceptors by ﬂuores-
cence microscopy. Binding afﬁnities and internalization proﬁles
were similar to those of endogenous receptors. With this study,
Papay et al. (2004) reported the ﬁrst mouse model expressing a
GPCR tagged with eGFP as a transgenic approach for in vivo
GPCR localization studies. The generation of knock-in animals
represented a further improvement by enabling for the ﬁrst time
to track down endogenous receptors, which has opened a new era
for pharmacological research.
KNOCK-IN HUMANIZED RHODOPSIN FUSED WITH A FLUORESCENT
PROTEIN (hRho-eGFP)
Chan et al. (2004) mouse lines expressing human rhodopsin-
eGFP were engineered using different knock-in strategies. All
mouse lines showed decreased expression levels of the fusion pro-
tein relative to the endogenous mouse rhodopsin. Comparing
the different homozygote mouse lines enabled to correlate the
decrease in human rhodopsin–eGFP expression to the increased
rate of retinal degeneration, providing a model of human dis-
eases. More recently, using a human mutant rhodopsin allele
[proline-to-histidine change at codon 23 (P23H) rhodopsin]
which induces mislocalization and degradation of the human
protein, the research group generated a knock-in mouse line
which modeled a common cause of autosomal dominant retini-
tis pigmentosa (Price et al., 2011). In humans, mutation Q344X
is responsible for a severe early onset form of retinitis pigmen-
tosa. The Q344X mutation introduces a premature stop codon
that prevents GFP expression in the human rhodopsin-eGFP con-
struct. Knock-in animals expressing this mutant construct were
used to monitor eGFP ﬂuorescence recovery as an index of the
frequency and timing of somatic mutations in the rhodopsin gene
(Sandoval et al., 2014). These mouse lines provided substantial
and valuable data concerning rhodopsin distribution in the retina
(for references, also see Table 2), and were advantageously imple-
mented for non-invasive measurement by illuminating the mouse
retina in live animals with blue light (Wensel et al., 2005). They
will provide a means to assess the impact of future gene-targeting
treatment strategies for retinal degeneration (Gross et al., 2006;
Sandoval et al., 2014).
OPIOID RECEPTORS
The opioid system modulates a wide range of physiological states,
of which nociception, reward,mood, stress, neuroendocrine phys-
iology, immunity, autonomic functions such as gastro-intestinal
transit (Kieffer and Evans, 2009; Walwyn et al., 2010; Chu Sin
Chung and Kieffer, 2013; Lutz and Kieffer, 2013). Opioid recep-
tors are members of the class A GPCR family, mu (MOP), delta
(DOP) and kappa (KOP) opioid receptors couple to inhibitory
heterotrimeric inhibitory G protein, and have high sequence
homology (Akil et al., 1998).
Mapping of receptor expression with neuronal resolution
Scherrer et al. (2006) generated a DOP-eGFP knock-in mouse line
by homologous recombination in which the coding sequence for
the DOP receptor fused to its C-terminus to the eGFP was inserted
at the Oprd1 locus.
Delta opioid-eGFP knock-in mice proved very helpful to map
DOP receptors in the nervous system and remedy the lack of
highly speciﬁc antibodies (see Table 2). In the peripheral ner-
vous system, DOP-eGFP receptors were detected in cell bodies
of speciﬁc peripheral sensory neuronal populations which pro-
cess sensory stimuli, namely mostly in large diameter myelinated
(Neuroﬁlament 200 positive), and in small diameter unmyelinated
non-peptidergic (Isolectin B4 positive) neurons (Scherrer et al.,
2009; Bardoni et al., 2014). The expression pattern of DOP-eGFP
receptors was also reported in mechanosensory organs in the skin
(Bardoni et al., 2014). Another study focused on the distribution of
DOP-eGFP in enteric neurons with DOP-eGFP expression mainly
in secretomotor neurons of the submucosal plexus of the digestive
tract (Poole et al., 2011). The observed distribution reﬂects func-
tional roles of DOP receptors in inhibition of intestinal motility
and absorption.
In the CNS, DOP-eGFP mapping was performed in the brain
and spinal cord (Erbs et al., 2014). Detailed DOP-eGFP expres-
sion was also reported in the hippocampus, where functional
DOP-eGFP was found to be mainly expressed in GABAergic
interneurons, mostly parvalbumin-positive ones (Erbs et al., 2012;
Rezai et al., 2013). The DOP-eGFP knock-in mice also enabled
to resolve the debate concerning the presence of DOP receptors
in principal cells. The absence of colocalization with calbindin
(Erbs et al., 2012) and presynaptic expression restricted to affer-
ents to glutamatergic principal cells established that no functional
DOP receptors are expressed under basal conditions in those cells
(Rezai et al., 2012). These results are consistent with a modulation
of principal cell activity in the hippocampus by DOP receptors,
and therefore an impact of the receptors in learning and memory.
More recently, a knock-in mouse line expressing a MOP recep-
tor fused with a RFP at the C-terminus, MOP-mcherry, was
generated by Erbs et al. (2014). At the Oprm1 locus, mcherry
cDNA was introduced into exon 4 of the MOP gene in frame
and 5′ from the stop codon. This FP is monomeric and highly
photostable, and the strong red signal of MOP-mcherry fusion
protein enabled direct identiﬁcation of neurons expressing MOP
in the nervous system (Erbs et al., 2014). The authors compiled the
DOP-eGFP andMOP-mcherry distributions in a neuroanatomical
atlas available at http://mordor.ics-mci.fr
Several studies in heterologous systems or cell culture had
suggested that MOP and DOP receptors may interact to form
heteromers (van Rijn et al., 2010; Rozenfeld et al., 2012; Stock-
ton and Devi, 2012) but their existence in vivo remains debated.
Co-immunoprecipitation studies performed on tissue from spinal
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Table 2 | Knock-in mice expressing GPCR-fluorescent protein fusions.
Fusion construct Biological readout Reference
hRhodopsin-eGFP Retinal degeneration kinetics
(model of recessive retinitis pigmentosa)
Chan et al. (2004)
Distribution, membrane structure, and trafﬁcking of rhodopsin
(model of retinitis pigmentosa)
Gross et al. (2006)
P23H-hRhodopsin-eGFP Degeneration and degradation kinetics of rhodopsin
(model of common cause of autosomal dominant retinitis
pigmentosa)
Price et al. (2011)
Q344X-hRhodopsin-
eGFP
DNA repair in photoreceptors cells during retinogenesis
(degeneration and degradation kinetics in a model of severe
early-onset of retinitis pigmentosa)
Sandoval et al. (2014)
DOP-eGFP Receptor distribution:
– central nervous system Scherrer et al. (2006, 2009), Erbs et al. (2014)
– hippocampus Erbs et al. (2012), Rezai et al. (2012, 2013)
– dorsal root ganglia Scherrer et al. (2009), Bardoni et al. (2014)
– mechanosensors in the skin Bardoni et al. (2014)
– myenteric plexus Poole et al. (2011)
Correlation between behavioral desensitization and receptor
internalization
Scherrer et al. (2006), Pradhan et al. (2009, 2010)
Biased agonism at the receptor
– pharmacological drugs
– endogenous opioid peptides
Pradhan et al. (2009, 2010)
Faget et al. (2012)
Behaviorally controlled receptor subcellular distribution Faget et al. (2012), Bertran-Gonzalez et al. (2013), Laurent
et al. (2014)
MOP-mcherry Receptor distribution in the central and peripheral nervous systems Erbs et al. (2014)
MOP-mcherry
x
DOP-eGFP
MOP-DOP neuronal co-expression in the brain Erbs et al. (2014)
cord or DRGs also hinted at close physical proximity between
the two receptors in these areas (Gomes et al., 2004; Xie et al.,
2009). In addition, MOP-DOP heteromers had been detected in
some brain areas using speciﬁc antibodies (Gupta et al., 2010).
Recently, extensive mapping of MOP-DOP neuronal colocal-
ization using double knock-in mice co-expressing DOP-eGFP
and MOP-mcherry provided sound data to investigate MOP-
DOP physical proximity and functional interactions. In the
hippocampus, a brain area where the two receptors are highly
co-expressed, co-immunoprecipitation experiments using anti-
bodies raised against the FPs indeed conﬁrmed physical proximity
(Erbs et al., 2014). These animals will now be useful to address
MOP-DOP speciﬁcities in ligand binding, signaling and trafﬁck-
ing as well as functional output and to investigate the potential of
MOP-DOP heteromers as a novel therapeutic target.
In vivo trafﬁcking, desensitization and behavioral output
The DOP-eGFP mouse line is the ﬁrst example of the
use of a knock-in line to study GPCR functions in vivo
(Scherrer et al., 2006). DOP agonist-induced internalization
was observed in vivo upon activation by the alkaloid [(+)-
4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5- dimethyl-1-piperazinyl)-
3-meth oxybenzyl]-N,N-diethylbenzamide] (SNC-80) and the
endogenous peptide Met-enkephalin (Scherrer et al., 2006). The
two agonists induce receptor internalization in heterologous sys-
tems with receptor phosphorylation as the ﬁrst step of a cascade
of events leading to termination of G protein dependent signaling,
receptor removal from the cell membrane and trafﬁcking to intra-
cellular compartments (Ferguson et al., 1996; von Zastrow and
Williams, 2012; Walther and Ferguson, 2013). DOP-eGFP mice
revealed that these agonists also induce receptor phosphorylation,
internalization via clathrin coated pits in vivo and degradation
in the lysosomal compartment in the brain (Scherrer et al., 2006;
Pradhan et al., 2009; Faget et al., 2012) and peripheral nervous
system in the myenteric plexus (Poole et al., 2011) and DRGs
(Scherrer et al., 2009). Moreover, these animals prove to be instru-
mental to decipher molecular mechanisms underlying receptor
desensitization leading to a loss of responsiveness of the receptor
upon stimulation by an agonist. Scherrer et al. (2006) were indeed
able, for the ﬁrst time, to establish the correlation between receptor
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trafﬁcking in vivo and the behavioral response: namely that the
receptor internalization induced by acute administration of the
agonist SNC-80was responsible for theobserved locomotordesen-
sitization. This paper was followed by additional studies exploring
the consequences of receptor pharmacological stimulation inmore
detail, in particular the concept of biased agonism.
G protein-coupled receptors have a ﬂexible and highly dynamic
nature (Moreira, 2014) which enables a given ligand to show
functional selectivity, that is, preferential activation of sig-
nal transduction pathways, otherwise termed biased agonism
(Ostrom and Insel, 2004; Giguere et al., 2014; Kenakin, 2014).
DOP-eGFP mice offer the possibility of addressing this con-
cept in vivo and to link it to a functional response. DOP-eGFP
mice were used to analyze the properties of two DOP recep-
tor agonists possessing similar signaling potencies and efﬁcacies
but with different internalization proﬁles (Pradhan et al., 2009).
SNC-80 and N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-
benzamide (AR-M100390), with high and low internalization
properties respectively, were systemically administered to mice,
and receptor trafﬁcking was correlated to induced anti-allodynic
effect in the context of inﬂammatory pain (Pradhan et al.,
2009). As expected, acute SNC-80 administration resulted in
receptor phosphorylation, decreased G protein coupling and
receptor degradation in the lysosomal compartment, leading to
desensitization with loss of anti-allodynic properties. On the
other hand, acute injection of AR-M100390 did not result in
receptor phosphorylation, did not reduce G protein coupling,
did not induce receptor internalization or desensitization but
retained analgesic properties. This study demonstrated that DOP
receptor localization determines its function in vivo and high-
lights the importance of receptor tracking in order to extricate
behavioral and cellular correlates of speciﬁc agonist properties
(Pradhan et al., 2009).
In a following study, DOP-eGFP mice were used to assess
the physiological impact of distinct signaling pathway recruit-
ment and/or adaptive responses upon chronic administration
of two DOP receptor agonists (Pradhan et al., 2010). Chronic
administration of SNC-80, which has high internalization prop-
erties, led to marked receptor downregulation and degradation
in SNC-80-tolerant animals. Receptor internalization prevented
any additional activation through physical disappearance from
the cell surface leading to general desensitization, as assessed
by thermal and mechanical analgesia, locomotor activity and
anxiety-related behavior. On the other hand, chronic admin-
istration of AR-M100390, with weak internalization properties,
did not cause changes in DOP-eGFP localization and induced
tolerance restricted to analgesia, with no effect on locomotor
activity or anxiolytic responses. These data show that a selective
internalization-independent tolerance was elicited and suggest the
occurrence of adaptativemechanisms that are network dependent.
These ﬁndings reinforce the importance of understanding ago-
nist speciﬁc signaling underlying biased agonism and tolerance.
Considering that drug design has focused on offering orthosteric
or allosteric modulators of GPCRs (Bradley et al., 2014), research
groups need to explore the downstream signaling cascades of these
drugs in more detail in order to understand and target the molecu-
lar events which underlie their efﬁcacy. This is an essential progress
for the understanding of drug action and opens new possibilities
for drug design.
Direct visualization of the receptor also permitted to deci-
pher the functional role of delta receptors in neuronal networks
and to understand the complex relation between behavior and
receptor subcellular distribution. Of particular interest is the
observation that DOP subcellular distribution is modiﬁed in two
brain areas involved in the processing of information associated
with emotional value or predicted outcome. The CA1 area of
the hippocampus is known to operate as a coincidence detec-
tor that reﬂects association of the context with strong emotional
stimuli of positive or aversive value (Duncan et al., 2012). Accord-
ingly, increased c-Fos immunoreactivity revealed activation of this
region in a drug-context association paradigm, and DOP-eGFP
internalization in this area therefore suggested a modulatory role
of the receptor in behavioral responses linked to context-induced
withdrawal (Faget et al., 2012). Along the same line, persistent
increase of DOP-eGFP expression at the cell surface of choliner-
gic interneurons was induced by conditioned training in the NAc
shell, which is involved in decision making and predictive reward
evaluation upon pavlovian conditioning (Bertran-Gonzalez et al.,
2013; Laurent et al., 2014).
Finally, the knock-in strategy revealed that the DOP-eGFP
internalization proﬁle in response to endogenous opioid release is
distinct from what is observed upon pharmacological stimulation
(Faget et al., 2012). Indeed, only part of the receptor population
present at the cell surface underwent internalization under physio-
logical conditions. This observation further highlights the need to
take into account the extent of changes that drug administration
induces in receptor cellular distribution.
Methodological improvements
Interestingly, DOP-eGFP knock in mice also bring useful techni-
cal insight. During the process of acute brain slice preparation for
electrophysiological recordings, DOP-eGFP revealed spontaneous
receptor internalization (Rezai et al., 2013). This event was likely
due to high glutamatergic activity in the hippocampus upon slic-
ing that leads to exitoxicity. Direct visualization of the receptor
therefore revealed a bias associated with previously unrecognized
receptor trafﬁcking that can now be addressed by initiating opti-
mization of slice preparation conditions for electrophysiological
recording (Rezai et al., 2013). This observation may be of partic-
ular relevance when addressing cellular responses elicited by drug
application.
CONCERNS ABOUT THE USE IN VIVO OF GPCR-FP FUSIONS
FOR FUNCTIONAL STUDIES
Despite the undeniably wide advances which have been and will
be brought by genetically engineered mice encoding ﬂuorescent
endogenous GPCRs, concerns were raised regarding the inherent
consequences of genetic manipulation. The possibility that the
observed localization does not entirely reﬂect the wild type recep-
tor distribution appears irrelevant since both MOP-mcherry and
DOP-eGFP receptor distributions in thebrain are in full agreement
with reports in mice and rats based on ligand binding (Kitchen
et al., 1997; Slowe et al., 1999; Goody et al., 2002; Lesscher et al.,
2003), GTPγS incorporation (Tempel and Zukin, 1987; Pradhan
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and Clarke, 2005) or mRNA detection [George et al., 1994; Man-
sour et al., 1995; Cahill et al., 2001; for a review see (LeMerrer
et al., 2009)]. Also, in a more detailed study,DOP-eGFP expression
in the hippocampus, mainly in parvalbumin-positive GABAergic
interneurons (Erbs et al., 2012), was corroborated by ISH studies
on DOP receptors (Stumm et al., 2004).
In the peripheral nervous system, despite previous reports sug-
gesting SP-dependent trafﬁcking of DOP receptors to the cell
membrane (Guan et al., 2005), Scherrer et al. (2009) reported
that DOP-eGFP almost never co-localized with substance P (SP)
in peripheral sensory neurons (Scherrer et al., 2009), a ﬁnd-
ing that was debated by others (Wang et al., 2010). A more
recent study addressed this discrepancy by comparing DOP-
eGFP cellular distribution to that of the native DOP receptor
using an ultrasensitive and speciﬁc ISH technique, which can
detect single mRNA molecules (Bardoni et al., 2014). Patterns
of DOP-eGFP distribution and Oprd1 mRNA expression were
found to be very similar and detectable in the same neuronal
populations, namely mostly in large diameter myelinated cells
(Neuroﬁlament 200 positive), and in small diameter unmyeli-
nated non-peptidergic neurons (isolectin B4 positive; Bardoni
et al., 2014). These data unambiguously conﬁrm that the expres-
sion proﬁle of the ﬂuorescent constructs mimics the endogenous
one and that ﬂuorescent knock-in mice can be reliably used
for mapping receptors in the central and peripheral nervous
system.
Regarding functional aspects, there has been no evidence so
far of any overt phenotypical or behavioral differences between
the DOP receptor knock-in strain and wild type animals (Scher-
rer et al., 2006; Pradhan et al., 2009, 2010; Rezai et al., 2013),
despite a twofold increase in mRNA and protein levels as well
as increased G protein activation compared to wild type ani-
mals (Scherrer et al., 2006). However, the possibility that the
subcellular distribution of the ﬂuorescent fusion does not reca-
pitulate that of the native untagged receptor is still debated.
Indeed, high surface expression of DOP-eGFP is observed under
basal conditions in several brain regions, particularly in the hip-
pocampus (Scherrer et al., 2009; Erbs et al., 2012, 2014; Faget
et al., 2012). This does not correlate with previous studies on
wild type receptors using electron microscopy or ﬂuorescent lig-
ands that indicated a predominant intracellular localization under
basal conditions and surface recruitment upon chronic mor-
phine or chronic pain condition (Cahill et al., 2001; Morinville
et al., 2004; Gendron et al., 2006; for review see Cahill et al.,
2007; Gendron et al., 2014). Surface expression of DOP-eGFP,
however, varies across CNS regions and neuronal type whereas
high ﬂuorescence is always visible within the cytoplasm (Erbs
et al., 2014). Accordingly, high surface expression appears to be
restricted to some neuronal types such as GABAergic interneurons
in the hippocampus or large proprioceptors in DRGs (Scher-
rer et al., 2006; Erbs et al., 2014). In many areas where DOP
receptors are highly expressed such as the striatum, the basal
ganglia, the amygdala or the spinal cord, DOP-eGFP is not
readily detected at the cell surface (Erbs et al., 2014) suggesting
that DOP-eGFP intracellular localization is predominant in those
neurons. Importantly, surface expression of DOP-eGFP can be
augmented under physiological stimulation (Bertran-Gonzalez
et al., 2013; Laurent et al., 2014; see above) or increased upon
chronic morphine treatment as previously reported for wild type
receptors (Erbs et al., unpublished data), strongly supporting that
the fused FP does not impact on the native subcellular distribution
of the receptor and that the latter can be modulated accord-
ing to the physiological state or modiﬁed upon pharmacological
treatment.
In the case of MOP-mcherry knock-in mice, the red ﬂu-
orescent signal is stronger inside the cell than at the plasma
membrane (Erbs et al., 2014). This distribution reﬂects actual
receptor intracellular distribution, as evidenced by comparison
with MOP-speciﬁc immunohistochemistry in heterozygous mice,
which conﬁrms that the fusion protein does not cause defec-
tive receptor localization or surface trafﬁcking (Erbs et al., 2014).
Importantly, MOP-mcherry retained unchanged receptor density
as well as [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO)
binding and efﬁcacy and agonist-induced internalization com-
pared to MOP. Moreover, behavioral effects of morphine in
knock-in mice were similar to wild type animals: acute and
chronic thermal analgesia, physical dependence, sensitization and
rewarding properties revealed no signiﬁcant differences with wild
type animals (Erbs et al., 2014). These data suggest that pre-
dominant intracellular localization of MOP-mcherry receptors
with low expression at the cell surface indeed reﬂect endogenous
wild type receptor subcellular distribution under basal condi-
tions, as observed in enteric neurons (Poole et al., 2011). In
addition, internalization kinetics of MOP-mcherry upon activa-
tion by the agonist DAMGO in hippocampal primary neuronal
cultures (Erbs et al., 2014) were similar to those reported for
DAMGO promoted internalization of endogenous wild type
receptors in the rat spinal cord (Trafton et al., 2000) and in
organotypic cultures of guinea pig ileum (Minnis et al., 2003) or
to Fluoro-dermorphin-induced sequestration in rat cortical pri-
mary neurons (Lee et al., 2002). This supports once again the
use of ﬂuorescent knock-in mice to study endogenous receptor
trafﬁcking. Of note, DAMGO promotes Flag-MOP receptor inter-
nalization with similar kinetics in transfected striatal primary
neurons (Haberstock-Debic et al., 2005), in adenovirus infected
primary cultures from DRG (Walwyn et al., 2006) or in neurons
of the locus coeruleus in brain slices from transgenic FLAG-MOP
receptor mice (Arttamangkul and Quillinan, 2008).
CONCLUSIONS AND IMPACT FOR DRUG DESIGN
Fluorescent knock-in mice represent a substantial technical
improvement in basic science. Precise identiﬁcation and local-
ization of the neurons expressing the GPCR of interest and
reliable monitoring of receptor subcellular localization are both
essential in understanding the physiopathological roles of endoge-
nous GPCRs. This was greatly anticipated, given the difﬁculties
encountered by many on the grounds of poor speciﬁcity of the
available antibodies for GPCR targeting. The main surprising
ﬁnding is maybe that the presence of the FP at the C-terminus
of the GPCR does not signiﬁcantly alter the behavioral out-
put: this observation fully validates the technology. However,
ﬂuorescent knock-in animals available to date target a hand-
ful of class A GPCRs only. The potency of the model being
now clearly established, one would expect rapid expansion to
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other receptors, in particular those with critical roles in human
pathologies. Forefront candidates include class C GABAB and
metabotropic glutamate receptors, both of which are involved
in a wide range of neurological disorders such as schizophre-
nia, neuropathic pain, cerebral ischemia, mood disorders and
substance abuse (Benes and Berretta, 2001; Delille et al., 2013;
Kumar et al., 2013). Fluorescent knock-in animals would enable
to revisit heterodimerization mechanisms, membrane targeting
and cellular distribution patterns of these obligatory heterodimers
in vivo. Furthermore, the relation between multimer scaffold
composition, in particular GABAB auxiliary subunits, and neu-
ronal or synaptic functions could also be readily examined to
reﬁne our current understanding of the variations in pharma-
cological and functional responses mediated by native receptors
(Gassmann and Bettler, 2012).
The knock-in mice bearing GPCR-FP fusions already con-
tributed to understanding the fundamental concepts of distinct
signaling or regulatory responses recruited by different agonists
of the same GPCR. These essential aspects of biased agonism
are a growing central concern in drug discovery in the hope of
developing strategies that ally high efﬁcacy with low or no side
effects. In addition, GPCR-FP fusions could bring considerable
knowledge regarding functional aspects of receptor activity and
internalization to evaluate the therapeutic potency of allosteric
modulators. This very active ﬁeld of research is mainly target-
ing class C GPCRs with well identiﬁed allosteric and orthosteric
binding sites such as metabotropic glutamate or GABAB receptors
but relevance for class A GPCRs is attracting increasing attention
(Nickols and Conn, 2014). Direct visualization of the neurons of
interest, either by FP under the control of a GPCR promoter or
by expression of the GPCR ﬂuorescent construct, also represents a
signiﬁcant breakthrough by making subsequent targeted investi-
gations available. This includes electrophysiological recordings on
previously identiﬁed cell, cell isolation by ﬂuorescence-activated
cell sorting for further biochemical (Western Blotting) and molec-
ular (RT-PCR) downstreamanalysis or highly speciﬁc and efﬁcient
immunoprecipitation of the interacting partners. The presence of
the FP also gives access to imaging techniques with which receptor
population tracking within membranes can be achieved, by ﬂuo-
rescence recovery after photobleaching or ﬂuorescence resonance
energy transfer. The latter also opens ways to identify heteromer
formation between GPCRs or between a GPCR and a ligand-gated
channel and to investigate in vivo their intracellular fate and impact
on signaling cascades. All these technological developments will
undeniably contribute to deepening our current knowledge of
GPCR controlled molecular and cellular processes and ultimately
will beneﬁt to drug design and screening.
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